Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | PMM2 | O15305 | 1/20 | 0.33 |
| ▸ | G6PD | P11413 | 1/20 | 0.33 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | PHOSPHO1 | Q8TCT1 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5511551 | 0.86 | CYP1A2 (0.40) | TYMSCYP1A2CYP2A6TSHRKIF11 | |
| SCHEMBL6041439 | 0.78 | TYMS (0.41) | TYMSCYP1A2CYP2A6TSHRCASP3 | |
| SCHEMBL30640484 | 0.78 | CYP1A2 (0.54) | CYP1A2CYP2A6TSHRALDH1A1MAPT | |
| SCHEMBL20967452 | 0.78 | TYMS (0.45) | TYMSCYP1A2CYP2A6CYP19A1TSHR | |
| SCHEMBL3267082 | 0.78 | CYP1A2 (0.54) | CYP1A2CYP2A6TSHRALDH1A1MAPT | |
| SCHEMBL21939792 | 0.78 | CYP1A2 (0.52) | TYMSCYP1A2CYP2A6CYP19A1TSHR | |
| SCHEMBL12819526 | 0.75 | PTGS1 (0.40) | TYMSCYP1A2CYP2A6CYP19A1TSHR | |
| SCHEMBL3267833 | 0.75 | CYP3A4 (0.43) | TYMSCYP1A2CYP2A6TSHRMEN1 | |
| SCHEMBL31040134 | 0.75 | CYP19A1 (0.42) | CYP1A2CYP19A1NFE2L2ACHEMAPT | |
| SCHEMBL30377849 | 0.74 | CYP1A2 (0.52) | TYMSCYP1A2CYP2A6CYP19A1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131144-A1 | AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-30 | — | — | US | disclosed |
| WO-2019016269-A1 | AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS | PHENEX-FXR GMBH (DE) | 2019-01-24 | — | — | WO | disclosed |
| EP-1914229-B1 | NOVEL CERCOSPORAMIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-06-16 | — | — | EP | disclosed |
| US-20090036492-A1 | Novel Cercosporamide Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-05 | — | — | US | disclosed |
| CN-101300244-A | Novel cercosporamide derivative | DAIICHI SANKYO CO LTD (JP) | 2008-11-05 | — | — | CN | disclosed |
| EP-1914229-A1 | NOVEL CERCOSPORAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036492-A1 | Novel Cercosporamide Derivative | GPR119, CBR3, SLC5A2 | TYMS 4095/4885CYP1A2 972/4885CYP2A6 572/4885 |
| US-20200131144-A1 | AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS | NR1H2, NR1H3, NR1H4 | TYMS 3646/4885CYP1A2 292/4885CYP2A6 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.